Clinical Trial Update: Effect of Omega-3 PUFA Supplementation in NAFLD Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing omega-3 PUFA supplementation in non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Omega-3 PUFA supplement (Omega-3 polyunsaturated fatty acids)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Non-Alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED